SGN 30

Drug Profile

SGN 30

Alternative Names: AC 10 mAb; Anti-CD30 antibody; SGN-30

Latest Information Update: 17 Nov 2009

Price : $50

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD30 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Hodgkin's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cutaneous T cell lymphoma; Hodgkin's disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 13 Nov 2006 Interim results from a phase II clinical trial in patients with cutaneous anaplastic large cell lymphoma have been added to the Cancer therapeutic trials sections
  • 16 May 2005 Phase-II clinical trials in Cutaneous T-cell lymphoma (ALCL) in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top